The findings demonstrate that MSLN-targeted CAR-T cells with PD-1 silencing have enhanced anti-tumor activity, indicating that silencing genes to target particular immune checkpoints may enhance CAR-T cell therapy for various types of cancer [25]. Here, MSLN is linked to neoplasm.